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Background: High serum levels of 25-hydroxyvitamin D (25(OH)D) have been found
among patients with a favorable disease course in relapsing-remitting MS (RRMS),
indicating that this may limit clinical deterioration. Clinical deterioration in RRMS correlates
with increasing serum levels of neurofilament light chain (NfL).
Objectives: To examine the association between physiological variations in serum
25(OH)D and NfL levels in RRMS patients before and during disease modifying
therapy (DMT).
Material and Methods: Serum 25(OH)D and NfL concentrations were measured in
85 newly diagnosed RRMS patients enrolled in a 24-month randomized double-blinded
placebo-controlled trial of ω-3 fatty acid supplementation without vitamin D. Patients
were without DMT until interferon β-1a (IFN-β) initiation at study month 6. Longitudinal
serum measurements and brain magnetic resonance imaging (MRI) were obtained.
Associations between 25(OH)D and NfL levels were analyzed with linear regression
models for the whole study period and the periods before and during IFN-β treatment.
Analyses with adjustment for inflammatory MRI disease activity were also performed.
Results: No significant associations were found between variations in 25(OH)D and
NfL levels during the whole study period (p = 0.95), or the periods without (p = 0.78)
or with (p = 0.33) IFN-β therapy. Patients with inflammatory MRI disease activity had
significantly higher serum NfL levels than patients without inflammatory MRI disease
activity [mean (SD) difference 12.6 (2.0) pg/mL, p < 0.01]. Adjustment for this did not
change the relationship between 25(OH)D and NfL concentrations.
Conclusion: Natural variations in serum 25(OH)D values do not seem to be associated
with alterations in serum NfL concentrations in RRMS patients.
Keywords: relapsing-remitting multiple sclerosis, 25-hydroxyvitamin D, neurofilament light chain, magnetic
resonance imaging, interferon-β
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INTRODUCTION
Central nervous tissue degeneration promotes disease
progression in multiple sclerosis (MS), and neurofilament
light chain (NfL) is a validated surrogate biomarker for this
process in patients with relapsing-remitting MS (RRMS) (1).
NfL is a major component of the cytoskeleton in neuronal axons
and levels of NfL in cerebrospinal fluid (CSF) and blood reflect
axonal loss in RRMS from an early disease stage (2). Moreover,
high serum concentrations of NfL have been associated with
inflammatory disease activity and development of atrophy on
brain magnetic resonance imaging (MRI) and clinical disability
(3). Disease modifying therapies (DMTs) reduce NfL levels in
RRMS patients, but it is currently unclear if this is due to their
anti-inflammatory properties, direct effect on neurodegeneration
or a combination of these actions (4, 5).
Naturally increasing serum levels of 25(OH)D have been
associated with decreased clinical and inflammatory MRI disease
activity in observational studies in RRMS (6, 7). Furthermore,
a good vitamin D status has been found to be associated with
low levels of NfL in CSF from MS patients in an observational
setting (8).
Results from randomized placebo-controlled trials (RCTs)
have indicated a relationship between increasing serum levels
of 25(OH)D after vitamin D supplementation and reduced
inflammatory MRI disease activity in RRMS (9). However, the
effect of vitamin D treatment on serum levels of NfL is uncertain,
as it has only been investigated in RCTs with a limited number of
rather clinically stable patients (10, 11).
Vitamin D intervention trials have not been able to obtain
MRI or clinical results in the magnitude of what was indicated by
earlier observational studies (6, 7). The natural variation in serum
25(OH)D concentrations in observational studies is largely
driven by seasonal differences in ultraviolet radiation (UVR)
exposure (12), and it has been speculated that discrepancies
between the results from observational studies of vitamin D and
RCTs of vitamin D supplementation in RRMS may among other
be related to UVR exposure having beneficial effects beyond
increasing the 25(OH)D serum level (9). It is therefore pertinent
to explore if observed natural variations in serum 25(OH)D
levels are related to neurodegeneration, as measured by change
in serum NfL levels, in RRMS.
We have previously reported results from a two-year
observational study of 85 RRMS patients with rather high
disease activity showing an inverse association between naturally
increasing 25(OH)D levels and inflammatory MRI disease
activity before introduction of interferon beta-1a (IFN-β)
treatment (6), while NfL levels were positively correlated with
inflammatory MRI disease activity and inversely with IFN-β
initiation (5). However, in a two-year double-blinded RCT of
high-dose oral vitamin D3 supplementation (20,000 IU/week)
in another cohort of 68 patients with RRMS with lower disease
activity we found only a strong trend for a reduction among
patients without DMTs and no overall effect of increasing serum
25(OH)D levels on serum levels of NfL (10). The aim of the
current study was therefore to clarify the potential relationship
between natural variations in 25(OH)D serum concentrations
and change in serum NfL levels both prior to and during IFN-β
therapy in our observational RRMS cohort.
MATERIALS AND METHODS
Trial Cohort and Design
Study details and clinical and MRI results have been published
earlier (13). Briefly, 92 Norwegian RRMS patients with age 18–
55 years, EDSS score ≤5, no use of DMTs the last 6 months,
and either ≥1 clinical relapse, new T1-weigheted gadolinium-
enhancing (T1 Gd+) or new or enlarging T2-weigheted MRI
lesion the last 12 months before baseline were included and
followed for 24 months. Inclusion was continuous throughout
the year from December 2004 to July 2006 and the patients
were allocated 1:1 to daily ω-3 (Triomar, Pronova Biocare AS,
Sandefjord, Norway) or placebo capsules both without vitamin D
for 24months. Treatment with thrice-weekly 44µg subcutaneous
IFN-β (Rebif, Merck Serono, Geneva, Switzerland) was initiated
at study month 6 for all and continued throughout the remaining
18 months of the trial for all but 5 patients. No other DMTs were
used during the study. The Regional Committee for Medical and
Health Research Ethics in Western Norway and the Norwegian
Medicines Agency approved the study protocol, written informed
consent was obtain from all patients before study-enrollment and
the study was registered at clinicaltrails.gov (NCT00360906).
Laboratory, Clinical and MRI
Measurements
Serum samples were available for measurements from baseline
and study months 3, 6, 12, and 24 for both NfL and
25(OH)D, and in addition at months 1, 7, 9, and 18 for
25(OH)D. Concentrations of 25(OH)D were determined by a
radioimmunoassay and NfL with a Simoa assay, as described
earlier (6, 14). Brain MRIs were acquired monthly the first nine
months and at months 12 and 24, as previously described (13).
Inflammatory MRI disease activity in the current study was
defined by the presence of new T1 Gd+ lesions.
TABLE 1 | Baseline characteristics.
Gender (women-men); N 57–31
Age (years); mean (SD) 38.9 (8.3)
Disease duration (years); mean (SD) 1.9 (3.1)
EDSS score; median (IQR) 2.0 (1.5–2.5)
HLA-DRB1*15 status (positive-negative); N 58–26†
BMI; mean (SD) 25.7 (4.3)
25(OH)D (nmol/L); mean (SD) 61.2 (19.3)‡
NfL (pg/mL); mean (SD) 40.2 (22.4)*
N, Number; SD, Standard deviation; IQR, Inter quartile range; EDSS, Kurtzke Expanded
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Missing Data and Statistical Analyses
Eighty-eight of the original 92 enrolled patients were included
in this study, and 3 of these patients only contributed with
25(OH)D and MRI measurements. Among the 85 patients with
NfL measurements, 10 had one missing value. Twenty-three out
of a possible total of 1020 scans were missing, with only one
patient having <10 scans. Baseline associations and correlations
between 25(OH)D and NfL and potential confounding factors
were analyzed with independent samples t-tests and Pearson
correlations. Comparisons between mean values at baseline
and end of study were examined with paired sample t-tests.
Associations between paired 25(OH)D and NfL levels and NfL
levels lagged 3 months behind 25(OH)D levels were analyzed
with linear regression models with random intercepts for each
patient for the whole study period and the periods without and
with IFN-β treatment. Models with adjustment for the effect of
MRI disease activity on NfL levels were calculated in additional
analyses. The intraclass correlation coefficient (ICC) for the NfL
measurements was calculated with a random effects model with
random intercepts for each patient. The analyses were performed
with IBM SPSS Statistics version 25 and R with the lme4 package.
RESULTS
Baseline Characteristics
Earlier reported baseline gender distribution, age, disease
duration, EDSS score, HLA-DRB1∗15 status and baseline
25(OH)D serum values (6), and body mass index (BMI)
FIGURE 1 | Mean (SD) serum levels of 25(OH)D and NfL throughout the study. Based on all available 25(OH)D and NfL measurements from a minimum of 85 and 79
patients, respectively, at each point of time.
FIGURE 2 | Mean (SD) serum levels of 25(OH)D and NfL levels throughout the calendar year for the whole study. Based on all available 25(OH)D and NfL
measurements from a minimum of 41 and 16 patients, respectively, at each month.
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and NfL serum levels are included together in Table 1. We
have previously found a positive correlation between baseline
25(OH)D and NfL levels and a negative correlation between
BMI and NfL measurements (10), but no similar correlations
or other associations or correlations were found between these
characteristics in the current cohort (data not shown). Still, high
levels of NfL were noted both at lower and higher levels of
25(OH)D (Supplemental figure 1).
Relationship Between Serum Levels of
25(OH)D and NfL
Although high-dose oral vitamin D supplementation has not
shown an effect on serumNfL levels in RRMS (10, 11), we wanted
to examine if there was a relationship between serum 25(OH)
and NfL concentrations in a setting where change in 25(OH)D
levels were mainly driven by seasonal variation in UVR exposure.
Previously reported 25(OH)D and NfL serum concentrations
during the 24-month study period are shown together in Figure 1
and Supplemental Table 1 (5, 6). As the measurements were
obtained within the same season, no significant change was found
between baseline and end of study values of 25(OH)D. However,
the NfL concentrations were significantly reduced from study
initiation to conclusion [mean (SD) level of 40.2 (22.4) and 28.2
(12.5) pg/mL, respectively, p < 0.01].
Due to the northern location of Norway, vitamin D
status varies substantially between winter (November to
March) and summer (May to September). Figure 2 and
Supplemental Table 2 show the serum 25(OH)D and NfL
concentrations from the whole study period stratified by calendar
month. The peak 25(OH)D level was found in August [mean
(SD) 102.3 (33.7) nmol/L] and the lowest value was seen in
March [mean (SD) 50.3 (16.8) nmol/L], while the highest NfL
FIGURE 3 | Mean (SD) serum levels of 25(OH)D and NfL levels throughout the calendar year before (A) and during (B) IFN-β treatment. (A) Based on all available
25(OH)D and NfL measurements from a minimum of 14 and 10 patients, respectively, at each month. (B) Based on all available 25(OH)D and NfL measurements from
a minimum of 18 and 2 patients, respectively, at each month.
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TABLE 2 | Change in serum NfL concentration with every 10 nmol/L increase of
25(OH)D.
Study period % (CI)* p-value*
Before IFN-β −0.3 (−2.0–1.5) 0.78
During IFN-β 1.6 (−1.6–4.8) 0.33
IFN-β, Interferon beta-1a; CI, 95% confidence interval.
*Calculated with linear regression models with random intercepts for each patient and
inclusion of only paired 25(OH)D and NfL measurements.
FIGURE 4 | Mean (SD) serum NfL levels in patients with and without new
T1-weighted gadolinium-enhancing (T1 Gd+) lesions on MRI scans
throughout the study. Based on all available NfL measurements from a
minimum of 79 patients at each point of time.
level was in February [mean (SD) 43.5 (27.7) pg/mL] and at
the bottom level in September [mean (SD) 28.9 (11.6) pg/mL].
However, no significant association was found when analyzing
paired 25(OH)D and NfL measurements for the whole study
period with a linear regression model [decrease of NfL of 0.1%
(95% CI−1.8−1.7%) with each 10 nmol/L increase of 25(OH)D,
p= 0.95].
We have earlier seen a trend for a reduction in serum
NfL levels among RRMS patients without DMTs on vitamin
D supplementation (10). Moreover, we have shown that
introduction of IFN-β therapy reduces NfL levels in the current
patient cohort (5). We therefore examined associations between
25(OH)D and NfL concentrations in the period before (study
month 0–6) and during (study month 7–24) IFN-β treatment
separately (Figure 3 and Supplemental Tables 3, 4). 25(OH)D
levels had expected seasonal variations and again the highest
value of NfL was found in winter [54.8 (31.6) pg/mL in February
prior to and 38.6 (32.4) pg/mL in November during IFN-
β therapy] and the lowest in summer [30.5 (11.0) pg/mL in
September prior to and 15.4 (7.7) in July during IFN-β therapy].
Nevertheless, no associations were found between change in
25(OH)D and NfL levels when the different study periods
were analyzed with linear regression models of paired samples
(Table 2).
Effect of MRI Activity on the Relationship
Between Serum Levels of 25(OH)D and NfL
Serum concentration of NfL rise with MRI disease activity in
RRMS patients (3, 5), and a significantly higher average NfL
TABLE 3 | Change in serum NfL concentration with every 10 nmol/L increase of
25(OH)D when controlling for MRI disease activity.
Study period % (CI)* p-value*
Whole 0.6 (−1.1–2.2) 0.49
Before IFN-β 0.1 (−1.8–1.9) 0.95
During IFN-β 1.4 (−1.8–4.6) 0.38
IFN-β, Interferon beta-1a; CI, 95% confidence interval.
*Calculated with linear regression models with random intercepts for each patient,
adjustment for T1-weigheted gadolinium-enhancing lesion activity on MRI and inclusion
of only paired 25(OH)D and NfL measurements.
concentration was found among patients with inflammatoryMRI
disease activity (T1 Gd+ scans) compared to those without such
MRI activity during the study [mean difference (SD) 12.6 (2.0)
pg/mL, p < 0.01] (Figure 4). In order to examine if changes in
25(OH)D levels were associated with alterations in NfL levels
independently of inflammatory activity, we performed additional
analyses of the relationship between the serum 25(OH)D and
NfL measurements with adjustment for the effect of MRI disease
activity on the NfL levels. However, this adjustment had no clear
effect, as no significant associations were seen between change in
25(OH)D levels and NfL concentrations during the whole study
period nor in the periods stratified by IFN-β use (Table 3).
DISCUSSION
This study explored the relationship between serum 25(OH)D
and NfL in RRMS in an observational setting, and is to
our knowledge the first longitudinal study examining the
potential relation of naturally varying 25(OH)D levels with
NfL concentrations in blood from RRMS patients with and
without DMT. The main result of the study is negative, as
we found no significant association between increasing levels
of 25(OH)D and change in NfL levels in serum in the two-
year study period. Likewise, no relationships were found in the
period before or after initiation of IFN-β treatment, nor when
controlling for the effect of inflammatory MRI disease activity on
the NfL concentration.
A good vitamin D status has earlier been associated with both
reduced MRI disease activity and clinical progression among
RRMS patients on IFN-β treatment in an observational setting
(15). However, our results do not support an effect of rising
25(OH)D levels driven mainly by seasonal alterations in UVR
exposure on axonal degeneration in RRMS, as measured by
serum NfL levels. This is in line with the finding of no effect of
high-dose oral vitamin D3 supplementation on serum NfL levels
in RCTs among RRMS patients with DMT (10, 11).
We previously reported a positive correlation between
baseline 25(OH)D and NfL serum levels that was not confirmed
in this patient cohort (10). However, we found high NfL levels
with both low and high 25(OH)D levels. Moreover, when
including measurements from the whole study and stratifying
patients into quartiles by their mean 25(OH)D level, the first and
fourth quartile had the highest average NfL levels at most time
points throughout the year (Figure 5). This may support earlier
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FIGURE 5 | Mean serum NfL concentrations during the year when stratified by 25(OH)D quartiles based on whole study mean values 1. quartile: 30.9–55.6 nmol/L; 2.
quartile: 56.1–65.8 nmol/L; 3. quartile: 66.2–78.3 nmol/L;4. quartile: 78.4–128.6 nmol/L.
observational data suggesting a clinical benefit in improvement
from a poor [25(OH)D < 25 nmol/L) to a sufficient (25(OH)D
∼ 50 nmol/L] vitamin D status (15), while an uncertain clinical
benefit of vitamin D supplementation has been found in RCTs
with an improvement from a sufficient to a good [25(OH)D >
75 nmol/L] vitamin D status (9). However, we and others did not
find an increase in NfL concentration in patients reaching high
25(OH)D levels during vitamin D intervention trials (10, 11).
The negative results reported herein may be due to several
different reasons. Although the 25(OH)D level in serum rise
rather quickly during summer and it is expected that levels in
the central nervous system will also increase within a rather
short time span (16), a possible positive effect of this on
neurodegeneration and a subsequent drop in serum NfL may
be more protracted. This may explain why we failed to find
a significant association between rising 25(OH)D and change
in NfL concentration during the six-month period without
DMT. However, the serum NfL levels seemed to decrease rather
quickly during summer, and no relationship was found when
analyzing the association between changes in 25(OH)D and
NfL levels with NfL measurements lagged three months behind
25(OH)D measurements (Supplemental Table 5). Moreover, we
have earlier shown a significant reduction in the serum NfL
concentration after IFN-β introduction in this patient cohort
(5). This may have overshadowed a limited relationship between
25(OH)D and NfL levels during IFN-β therapy, similarly to
what was seen in our earlier report on serum inflammation
markers among these patients (17). Furthermore, although a
negative association between increasing 25(OH)D levels and
inflammatory MRI disease activity and a positive association
between inflammatory MRI disease activity and NfL levels have
been reported in this cohort (5, 6), it is clear that axonal
degeneration is not only driven by neruoinflammation (18).
Lastly, it may be speculated that inter-individual differences in
serum levels of 25(OH)D at a given time point are related to
differing inflammatory disease activity (9), and that seasonal
variation in inflammatory MRI disease activity and NfL levels
are due to seasonal beneficial factors for both neuroinflammation
and neurodegeneration not related to 25(OH)D or UVR
exposure (9, 19).
The current study has several limitations. Firstly, the total
number of enrolled patients and NfL measurements were limited
when taking into account that half of the total variation of the NfL
levels was inter-individual (ICC of 0.50). Secondly, the 25(OH)D
levels of the patients were rather high throughout the year with
mean concentrations being over 50 nmol/L everymonth. Thirdly,
the period of time the patients were without DMT was short,
and even though the time interval between serum measurements
during DMT treatment was quite long we cannot rule out that
changes in serum 25(OH)D levels may be related to alternations
in NfL serum concentrations beyond the timeframe of this study.
However, the belief in the main result may be strengthened by
the study design and its stringent conduction, as it was originally
designed as a RCT ofω-3 supplementation. Specifically, it should
be noted that the continuous enrollment throughout the year lead
to a quite even amount of measurements being obtained during
winter and summer time. Moreover, the strength of the results is
increased by the consistent outcome in the overall and sub-period
analyses, and in the adjusted analyses.
Although an increase in serum 25(OH)D levels may reduce
short-term MRI activity among vitamin D sufficient RRMS
patients, it is still unclear if this has a long-term effect on axonal
degeneration and disability progression (9). Furthermore, the
positive effect of a high 25(OH)D level on brain atrophy in an
observational setting seems to be in conflict with no reduction
in serum NfL levels in RCTs of vitamin D supplementation
(10, 11, 15). It is therefore advisable that further studies on
25(OH)D and NfL should be carried out in short-term RCTs
with vitamin D supplementation as an add-on to other DMTs in
patients with a poor vitamin D status, and in larger and more
long-term observational studies among patients that are vitamin
D sufficient.
In conclusion, the results from this observational study do
not support a significant association between naturally increasing
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25(OH)D serum levels and neurodegeneration, as measured by
change in serum levels of NfL, in RRMS patients prior to or
during IFN-β treatment.
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